Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
122 hedge funds and large institutions have $437M invested in Mersana Therapeutics in 2021 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 15 closing their positions.
100% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 15
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
12% more funds holding
Funds holding: 109 → 122 (+13)
0.07% more ownership
Funds ownership: 3.83% → 3.9% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
33% less capital invested
Capital invested by funds: $648M → $437M (-$212M)
91% less call options, than puts
Call options by funds: $92K | Put options by funds: $1.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$13.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.37M |
| 3 |
D.E. Shaw & Co
New York
|
+$4.64M |
| 4 |
Morgan Stanley
New York
|
+$4.36M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$21.1M |
| 2 |
Alkeon Capital Management
New York
|
-$17M |
| 3 |
BlackRock
New York
|
-$10.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.71M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.74M |
MRSN Hedge Fund Activity: Q4 2021 in Review
122 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2021, worth a combined $437M — down 33% from $648M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new MRSN positions and 15 closed out — a net gain of 15 holders — while 45 added to existing stakes and 24 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $13.2M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $21.1M sold.
- 122 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2021, up from 109 in Q3 2021.
- Funds reported $437M of Mersana Therapeutics stock for Q4 2021, down 33% quarter-over-quarter.
- 30 funds opened new Mersana Therapeutics positions in Q4 2021 and 15 closed out, a net change of +15 holders.
- The largest Mersana Therapeutics buyer in Q4 2021 was Bain Capital Life Sciences Investors, an estimated $13.2M added.
- The largest Mersana Therapeutics seller in Q4 2021 was Pictet Asset Management (Switzerland), an estimated $21.1M sold.
Based on aggregated 13F filings for Q4 2021.